WALTHAM, Mass., Feb. 5, 2015 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., today announced that chief executive officer, Arlene Morris, will be presenting a corporate overview at the 17th Annual BIO CEO and Investor Conference at 10:00 a.m. EST on Monday, February 9, 2015, in the Park South room at the Waldorf Astoria Hotel in New York City.
About Syndax
Syndax is developing Entinostat, an oral, highly selective HDAC inhibitor with epigenetic and immunomodulatory activity that is being evaluated in multiple combination approaches for the treatment of patients with therapy-resistant cancers. Entinostat has been designated a Breakthrough Therapy by the FDA when used in combination with exemestane in HR+ advanced (locally advanced or metastatic) breast cancer. A pivotal Phase 3 clinical study combining entinostat with exemestane for the treatment of hormone receptor-positive metastatic breast cancer is currently enrolling. Syndax is also developing an immuno-oncology platform to improve responsiveness to checkpoint inhibitors based on entinostat’s ability to down-regulate immune suppressor cells. Syndax holds rights to entinostat in most major markets.
Syndax Contacts
Corporate:
Bob Goodenow
Chief Business Officer
Syndax Pharmaceuticals
(781) 419-1418
bgoodenow@syndax.com
Investor:
Robert Flamm, Ph.D.
Russo Partners
(212) 845-4226
robert.flamm@russopartnersllc.com
Media:
David Schull or Matt Middleman, M.D.
Russo Partners
(212) 845-4271
(212) 845-4272
david.schull@russopartnersllc.com
matt.middleman@russopartnersllc.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/syndax-to-present-at-2015-bio-ceo--investor-conference-300031610.html
SOURCE Syndax Pharmaceuticals, Inc.
Help employers find you! Check out all the jobs and post your resume.
